Holen Sie sich die Stockscreener-App
15.83
8.02%
-1.38
Handel nachbörslich:
15.76
-0.07
-0.44%
Contineum Therapeutics Inc Aktie (CTNM) Neueste Nachrichten
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain - BioSpace
Contineum Therapeutics Secures FDA Authorization for Novel Pain Treatment PIPE-791 | CTNM Stock News - StockTitan
(CTNM) Trading Signals - Stock Traders Daily
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation - Yahoo Finance
Contineum Therapeutics to Attend Upcoming Investor Conferences - BioSpace
Contineum Therapeutics Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World
Contineum Therapeutics' SWOT analysis: promising pipeline drives stock outlook - Investing.com
Contineum Therapeutics (NASDAQ:CTNM) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Royal Bank of Canada Lowers Contineum Therapeutics (NASDAQ:CTNM) Price Target to $31.00 - MarketBeat
Ionis to present at upcoming investor conferences - Quantisnow
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - BioSpace
Contineum (CTNM) Reports Strong Trial Progress, $214M Cash Runway Through 2027 | CTNM Stock News - StockTitan
Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - Quantisnow
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - Quantisnow
(CTNM) Proactive Strategies - Stock Traders Daily
Contineum Therapeutics (NASDAQ:CTNM) Stock Rating Upgraded by Baird R W - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Upgraded at Baird R W - MarketBeat
Ionis to hold third quarter 2024 financial results webcast - Quantisnow
Baird bullish on Contineum Therapeutics stock, sees upside from early-stage trials - Investing.com Canada
Contineum stock draws bullish view at Baird (CTNM:NASDAQ) - Seeking Alpha
Contineum Therapeutics (NASDAQ:CTNM) Research Coverage Started at Robert W. Baird - MarketBeat
Baird bullish on Contineum Therapeutics stock, sees upside from early-stage trials By Investing.com - Investing.com South Africa
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis - Quantisnow
EVP Research Swayze Eric converted options into 125 shares and sold $2,031 worth of shares (53 units at $38.31) (SEC Form 4) - Quantisnow
Objective long/short (CTNM) Report - Stock Traders Daily
The US IPO Engine Looks Ready to Speed Ahead in Second Quarter - MSN
Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28% - Yahoo Finance
Financial Metrics Exploration: Understanding Contineum Therapeutics Inc. (CTNM) Through Ratios - The Dwinnex
Squarepoint Ops LLC Invests $2.64 Million in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
SEC Form 4 filed by EVP, Chief Human Resourses Ofc Devers Shannon L. - Quantisnow
New insider Devers Shannon L. claimed ownership of 7,909 shares (SEC Form 3) - Quantisnow
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum - Yahoo Finance
Rhumbline Advisers Makes New Investment in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Trading 5% Higher - Defense World
Perceptive Advisors LLC Purchases Shares of 1,566,668 Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
Wall Street SWOT: Contineum Therapeutics stock rides wave of promising assets - Investing.com
Bank of New York Mellon Corp Invests $356,000 in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
(CTNM) Investment Analysis and Advice - Stock Traders Daily
Sandia Investment Management LP Takes $88,000 Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics, Inc.'s Lock-Up Period Will End on October 2nd (NASDAQ:CTNM) - MarketBeat
Contineum Therapeutics, Inc.'s Lock-Up Period To End on October 2nd (NASDAQ:CTNM) - MarketBeat
CD Projekt (OTCMKTS:OTGLY) Shares Up 2.8% - Defense World
Contineum Therapeutics, Inc.’s Lock-Up Period To End on October 2nd (NASDAQ:CTNM) - Defense World
BW LPG (OTCMKTS:BWLLY) Stock Price Down 0.1% - Defense World
NET Power Inc. (NYSE:NPWR) Major Shareholder Sells $12,348.00 in Stock - Defense World
Direxion Daily MSFT Bull 2X Shares Announces Quarterly Dividend of $0.33 (NASDAQ:MSFU) - Defense World
Hilton Worldwide Holdings Inc. (NYSE:HLT) Shares Acquired by Xponance Inc. - Defense World
Blue Star Gold (CVE:BAU) Shares Down 9.1% - Defense World
Bank of Nova Scotia (TSE:BNS) Lifted to “Strong-Buy” at Cibc World Mkts - Defense World
Zacks Research Comments on Vail Resorts, Inc.’s FY2024 Earnings (NYSE:MTN) - Defense World
Mill Creek Capital Advisors LLC Makes New Investment in Vanguard High Dividend Yield ETF (NYSEARCA:VYM) - Defense World
Evergreen Capital Management LLC Acquires 519 Shares of BlackRock, Inc. (NYSE:BLK) - Defense World
Origin Enterprises (LON:OGN) Sets New 12-Month High After Dividend Announcement - Defense World
Q3 2024 Earnings Estimate for Biogen Inc. (NASDAQ:BIIB) Issued By Wedbush - Defense World
Kenvue (NYSE:KVUE) Downgraded by Royal Bank of Canada - Defense World
Ionis Plans $500M Public Offering - San Diego Business Journal
Contineum Therapeutics (NASDAQ:CTNM) Sees Strong Trading Volume - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Sees Large Volume Increase - MarketBeat
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):